As of 2025-05-16, the EV/EBITDA ratio of Iovance Biotherapeutics Inc (IOVA) is -1.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IOVA's latest enterprise value is 473.02 mil USD. IOVA's TTM EBITDA according to its financial statements is -333.51 mil USD. Dividing these 2 quantities gives us the above IOVA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 13.3x | 13.1x |
| Forward P/E multiples | 15.6x - 36.6x | 19.0x |
| Fair Price | (15.28) - (12.98) | (15.69) |
| Upside | -968.0% - -837.5% | -991.3% |
| Date | EV/EBITDA |
| 2025-05-15 | -1.42 |
| 2025-05-14 | -1.36 |
| 2025-05-13 | -1.45 |
| 2025-05-12 | -1.59 |
| 2025-05-09 | -1.41 |
| 2025-05-08 | -2.83 |
| 2025-05-07 | -2.79 |
| 2025-05-06 | -2.76 |
| 2025-05-05 | -3.16 |
| 2025-05-02 | -3.16 |
| 2025-05-01 | -2.99 |
| 2025-04-30 | -3.25 |
| 2025-04-29 | -3.22 |
| 2025-04-28 | -3.27 |
| 2025-04-25 | -3.17 |
| 2025-04-24 | -3.02 |
| 2025-04-23 | -2.85 |
| 2025-04-22 | -2.87 |
| 2025-04-21 | -2.74 |
| 2025-04-17 | -2.72 |
| 2025-04-16 | -2.73 |
| 2025-04-15 | -2.89 |
| 2025-04-14 | -3.07 |
| 2025-04-11 | -2.96 |
| 2025-04-10 | -2.72 |
| 2025-04-09 | -2.93 |
| 2025-04-08 | -2.51 |
| 2025-04-07 | -2.69 |
| 2025-04-04 | -2.66 |
| 2025-04-03 | -2.91 |
| 2025-04-02 | -3.20 |
| 2025-04-01 | -2.91 |
| 2025-03-31 | -2.99 |
| 2025-03-28 | -3.22 |
| 2025-03-27 | -3.29 |
| 2025-03-26 | -3.10 |
| 2025-03-25 | -3.14 |
| 2025-03-24 | -3.29 |
| 2025-03-21 | -3.20 |
| 2025-03-20 | -3.20 |
| 2025-03-19 | -3.22 |
| 2025-03-18 | -3.23 |
| 2025-03-17 | -3.40 |
| 2025-03-14 | -3.25 |
| 2025-03-13 | -3.18 |
| 2025-03-12 | -3.48 |
| 2025-03-11 | -3.56 |
| 2025-03-10 | -3.39 |
| 2025-03-07 | -3.41 |
| 2025-03-06 | -3.41 |